We will work closely with the FDA and the third-party manufacturer to address the feedback as quickly as possible in order to bring the first HER3 directed medicine to patients with previously-treated EGFR-mutated non-small cell lung cancer, said Ken Takeshita, MD, Global Head, R&D, Da
Date: Jun 26, 2024
Category: Business
Source: Google
Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial
Ken Takeshita, MD, Global Head, Oncology R&D, Daiichi Sankyo, said: We are encouraged by the statistically significant results of the dual primary endpoint of progression-free survival seen with datopotamab deruxtecan and look forward to the final overall survival analysis. We plan to share the